Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration

Overview

The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral intravitreally transplantation of adult bone marrow stem cells in subjects with geographic atrophy secondary to age-related macular degeneration.

Full Title of Study: “Intravitreal Injection of Human Bone Marrow Derived Mesenchymal Stem Cell in Patients With Dry Age-related Macular Degeneration(AMD)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2015

Detailed Description

This study is an open-label investigation of the safety and preliminary efficacy of unilateral intravitreal injection of autologous bone marrow stem cells in subjects with Geographic Atrophy secondary to Age-Related Macular Degeneration (AMD). Subjects will be enrolled based on specific inclusion/exclusion criteria and evaluated at regular post transplant intervals.

Human central nervous system -stem cells will be transplanted by a vitreoretinal surgeon. The transplantation will be conducted in the eye with the inferior best-corrected visual acuity (BCVA) (i.e., the Study Eye). Only the Study Eye will undergo transplantation. The adult bone marrow stem cells will be administered into the vitreous cavity through a standard surgical approach.

Moxifloxacin 300 mg(once per day ) will be administered orally to all subjects for a period of five days ( 2 days pre and post operatively) .

Subjects will be monitored frequently for a total of one year after adult bone marrow stem cells cell injection .

Interventions

  • Drug: autologous bone marrow derived stem cells
    • intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume

Arms, Groups and Cohorts

  • Experimental: autologous bone marrow stem cells
    • use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients

Clinical Trial Outcome Measures

Primary Measures

  • number of subjects with adverse events
    • Time Frame: 6 months
    • Descriptive analysis of frequency and types of adverse events experienced by each subject during the study period

Secondary Measures

  • Assessment of visual function changes from the base line
    • Time Frame: 6 months
    • assessment will include Change in the mean of BCVA, Optical Coherence Tomography imaging, fluorescein angiography, slitlamp examination with fundus photography, Electroretinographic evidence (mfERG) showing enhanced activity in the location

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of age-related macular degeneration with geographic atrophy (GA)
  • Only patients with a specific degree and extent of GA will be eligible
  • Subjects with best-corrected visual acuity (BCVA) of less than or equal to 20/400 in the Study Eye
  • No prior or current choroidal neovascularization in either eye
  • Able to provide written informed consent prior to any study related procedures
  • Agree to comply in good faith with all conditions of the study and to attend all required study visits

Exclusion Criteria

  • Prior vitreal or retinal surgery in the previous 6 months
  • Glaucoma
  • Atrophic macular disease of any other cause
  • Diabetic retinopathy or diabetic macular edema in either eye
  • Previous organ, tissue or bone marrow transplantation
  • Autoimmune disease
  • Allergy to moxifloxacin
  • Current or prior malignancy (or is on chemotherapy)

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Al-Azhar University
  • Collaborator
    • Hassan , Hosny , M.D. M.Sc
  • Provider of Information About this Clinical Study
    • Principal Investigator: abdelhakim mohamed safwat, assistant lecturer ophthalmology department al-azhar university – Al-Azhar University
  • Overall Contact(s)
    • Abdelhakim mohamed safwat, M.D., +201005151919, abdelhakimsafwat@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.